NCT00939627 2026-03-10Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabNational Cancer Institute (NCI)Phase 2 Completed55 enrolled 10 charts
NCT00588770 2026-03-03Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI)Phase 3 Active not recruiting403 enrolled 10 charts